AR034854A1 - Compuesto de imidazol condensado, prodroga del mismo, composición farmaceutica y agente para reducir androgenos que lo contienen ,metodo para producirlo, sal diastereomerica de dicho compuesto y metodo para producir un compuesto opticamente activo del compuesto - Google Patents
Compuesto de imidazol condensado, prodroga del mismo, composición farmaceutica y agente para reducir androgenos que lo contienen ,metodo para producirlo, sal diastereomerica de dicho compuesto y metodo para producir un compuesto opticamente activo del compuestoInfo
- Publication number
- AR034854A1 AR034854A1 ARP010105365A ARP010105365A AR034854A1 AR 034854 A1 AR034854 A1 AR 034854A1 AR P010105365 A ARP010105365 A AR P010105365A AR P010105365 A ARP010105365 A AR P010105365A AR 034854 A1 AR034854 A1 AR 034854A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- produce
- agent
- androgens
- imidazol
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 4
- 230000003287 optical effect Effects 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 239000003098 androgen Substances 0.000 title 1
- 229940030486 androgens Drugs 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010036976 Prostatism Diseases 0.000 abstract 1
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000030270 breast disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 206010046766 uterine cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicinal Preparation (AREA)
Abstract
Un compuesto que tiene una actividad inhibidora sobre la esteroide C17-20-liasa, y útil para el tratamiento y la profilaxis de un tumor tal como prostatismo, cáncer mamario, cáncer uterino, cáncer ovárico, mastopatía, histeromioma, endometriosis, y similares, y un método para separar eficientemente un compuesto ópticamente activo de este compuesto de una ,mezcla de isómeros ópticos del mismo. El compuesto es de la fórmula 1 en donde n es un entero de 1 a 3 y Ar es un anillo aromático opcionalmente sustituido, una sal del mismo o una prodroga del mismo, y un método para obtener un compuesto ópticamente activo resolviendo ópticamente una mezcla de isómeros ópticos mediante el uso de un agente de resolución. tal como ácido tartranílico y similares.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000351780 | 2000-11-17 | ||
| JP2001247618 | 2001-08-17 | ||
| JP2001336880 | 2001-11-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034854A1 true AR034854A1 (es) | 2004-03-24 |
Family
ID=27345219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010105365A AR034854A1 (es) | 2000-11-17 | 2001-11-16 | Compuesto de imidazol condensado, prodroga del mismo, composición farmaceutica y agente para reducir androgenos que lo contienen ,metodo para producirlo, sal diastereomerica de dicho compuesto y metodo para producir un compuesto opticamente activo del compuesto |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7141598B2 (es) |
| EP (2) | EP1334106B1 (es) |
| JP (2) | JP3753971B2 (es) |
| KR (3) | KR20080002929A (es) |
| CN (3) | CN100572363C (es) |
| AR (1) | AR034854A1 (es) |
| AT (2) | ATE327237T1 (es) |
| AU (3) | AU1429602A (es) |
| BR (1) | BR0115306B1 (es) |
| CA (1) | CA2429133C (es) |
| CY (1) | CY1105423T1 (es) |
| DE (1) | DE60119963T2 (es) |
| DK (1) | DK1334106T3 (es) |
| ES (1) | ES2260303T3 (es) |
| HU (1) | HU229408B1 (es) |
| IL (2) | IL155624A0 (es) |
| MX (1) | MXPA03004347A (es) |
| MY (1) | MY134929A (es) |
| NO (1) | NO326366B1 (es) |
| NZ (1) | NZ526387A (es) |
| PE (1) | PE20020596A1 (es) |
| PL (1) | PL204934B1 (es) |
| PT (1) | PT1334106E (es) |
| SI (1) | SI1334106T1 (es) |
| TW (1) | TWI306099B (es) |
| WO (1) | WO2002040484A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2700690C (en) * | 2002-01-10 | 2013-09-10 | Takeda Pharmaceutical Company Limited | Process for producing reformatsky reagent in stable form |
| WO2004075890A1 (ja) * | 2003-02-26 | 2004-09-10 | Takeda Pharmaceutical Company | 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾ－ル誘導体の安定化方法 |
| JP4745616B2 (ja) * | 2003-02-26 | 2011-08-10 | 武田薬品工業株式会社 | 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾール誘導体の安定化方法 |
| US20060177506A1 (en) * | 2003-03-17 | 2006-08-10 | Shigeo Yanai | Release control compositions |
| JP4837895B2 (ja) * | 2003-03-17 | 2011-12-14 | 武田薬品工業株式会社 | 放出制御組成物 |
| JP5070042B2 (ja) * | 2004-05-03 | 2012-11-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 選択的アンドローゲン受容体モジュレーター（ｓａｒｍｓ）としての新規インドール化合物 |
| BRPI0511621A (pt) * | 2004-05-28 | 2008-01-02 | Speedel Experimenta Ag | compostos orgánicos |
| WO2006093353A1 (ja) | 2005-03-03 | 2006-09-08 | Takeda Pharmaceutical Company Limited | 放出制御組成物 |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| AR056888A1 (es) * | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
| AU2007212191B2 (en) * | 2006-02-10 | 2011-12-22 | Janssen Pharmaceutica N.V. | Novel imidazolopyrazole derivatives useful as selective androgen receptor modulators |
| TW200804284A (en) * | 2006-03-31 | 2008-01-16 | Speedel Experimenta Ag | Process for preparing 6,7-dihydro-5H-imidazo[1,5-a]pyridin-8-one |
| AR069079A1 (es) * | 2007-10-29 | 2009-12-30 | Takeda Pharmaceutical | Farmaco para la prevencion o el tratamiento de cancer |
| JOP20190230A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| UY33740A (es) * | 2010-11-18 | 2012-05-31 | Takeda Pharmaceutical | Método para tratar el cáncer de mama y cáncer de ovarios |
| WO2012133918A1 (en) | 2011-04-01 | 2012-10-04 | Takeda Pharmaceutical Company Limited | Solid preparation |
| AU2012270496A1 (en) | 2011-06-15 | 2013-12-19 | Takeda Pharmaceutical Company Limited | Production method of imidazole derivatives |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4728645A (en) * | 1982-12-21 | 1988-03-01 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives and other substituted bicyclic derivatives, useful as aromatase inhibitors |
| NZ221729A (en) | 1986-09-15 | 1989-07-27 | Janssen Pharmaceutica Nv | Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions |
| CA1326234C (en) | 1987-04-22 | 1994-01-18 | Michael R. Angelastro | 17.beta.-(cyclopropylamino)androst-5-en-3.beta.-ol and related compoundsuseful as_c__-__ lyase inhibitors |
| US5057521A (en) * | 1988-10-26 | 1991-10-15 | Ciba-Geigy Corporation | Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism |
| US4966898A (en) | 1989-08-15 | 1990-10-30 | Merrell Dow Pharmaceuticals Inc. | 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors |
| EP0573534B1 (en) | 1991-03-01 | 1998-12-23 | Electrostatic Technology, Inc. | Powder coating method for producing circuit board laminae and the like |
| US5457102A (en) | 1994-07-07 | 1995-10-10 | Janssen Pharmaceutica, N.V. | Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives |
| HU222117B1 (hu) * | 1992-01-27 | 2003-04-28 | Janssen Pharmaceutica N.V. | Pirrolo[1,2-c] imidazolil- és imidazo[1,5-a] piridil-csoporttal szubsztituált 1H-benzimidazol-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítmények |
| WO1993020097A1 (en) | 1992-03-31 | 1993-10-14 | British Technology Group Ltd. | 17-substituted steroids useful in cancer treatment |
| GB9310635D0 (en) | 1993-05-21 | 1993-07-07 | Glaxo Group Ltd | Chemical compounds |
| NZ273681A (en) | 1993-09-30 | 1996-09-25 | Yamanouchi Pharma Co Ltd | Fluoroenylmethylazole derivatives (including tricyclic ring systems where the middle ring is heterosubstituted) |
| WO1996014090A1 (en) | 1994-11-07 | 1996-05-17 | Janssen Pharmaceutica N.V. | Compositions comprising carbazoles and cyclodextrins |
| AU6015796A (en) | 1995-06-14 | 1997-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Fused imidazole derivatives and medicinal composition thereof |
| US6420375B1 (en) | 1997-02-21 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Fused ring compounds, process for producing the same and use thereof |
| EP1028110B1 (en) | 1997-10-02 | 2004-04-14 | Daiichi Pharmaceutical Co., Ltd. | Novel dihydronaphthalene compounds and process for producing the same |
| CA2328973A1 (en) | 1998-04-23 | 1999-10-28 | Akio Ojida | Naphthalene derivatives, their production and use |
| PE20010781A1 (es) * | 1999-10-22 | 2001-08-08 | Takeda Chemical Industries Ltd | Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion |
-
2001
- 2001-11-16 AR ARP010105365A patent/AR034854A1/es active IP Right Grant
- 2001-11-16 HU HU0400549A patent/HU229408B1/hu not_active IP Right Cessation
- 2001-11-16 KR KR1020077025704A patent/KR20080002929A/ko not_active Withdrawn
- 2001-11-16 CN CNB2005100640723A patent/CN100572363C/zh not_active Expired - Fee Related
- 2001-11-16 NZ NZ526387A patent/NZ526387A/en not_active IP Right Cessation
- 2001-11-16 PL PL362766A patent/PL204934B1/pl unknown
- 2001-11-16 AU AU1429602A patent/AU1429602A/xx active Pending
- 2001-11-16 US US10/416,986 patent/US7141598B2/en not_active Expired - Lifetime
- 2001-11-16 WO PCT/JP2001/010002 patent/WO2002040484A2/en not_active Ceased
- 2001-11-16 KR KR1020057018247A patent/KR100809899B1/ko not_active Expired - Fee Related
- 2001-11-16 MX MXPA03004347A patent/MXPA03004347A/es active IP Right Grant
- 2001-11-16 MY MYPI20015279A patent/MY134929A/en unknown
- 2001-11-16 AU AU2002214296A patent/AU2002214296C1/en not_active Ceased
- 2001-11-16 IL IL15562401A patent/IL155624A0/xx active IP Right Grant
- 2001-11-16 TW TW090128440A patent/TWI306099B/zh not_active IP Right Cessation
- 2001-11-16 CN CNB018190251A patent/CN1329394C/zh not_active Expired - Fee Related
- 2001-11-16 EP EP01982800A patent/EP1334106B1/en not_active Expired - Lifetime
- 2001-11-16 CA CA002429133A patent/CA2429133C/en not_active Expired - Fee Related
- 2001-11-16 KR KR1020037006727A patent/KR100725442B1/ko not_active Expired - Fee Related
- 2001-11-16 DE DE60119963T patent/DE60119963T2/de not_active Expired - Lifetime
- 2001-11-16 JP JP2001351035A patent/JP3753971B2/ja not_active Expired - Fee Related
- 2001-11-16 CN CNA200610100666XA patent/CN1900079A/zh active Pending
- 2001-11-16 DK DK01982800T patent/DK1334106T3/da active
- 2001-11-16 EP EP05077705.1A patent/EP1681290B9/en not_active Expired - Lifetime
- 2001-11-16 AT AT01982800T patent/ATE327237T1/de active
- 2001-11-16 BR BRPI0115306-4B1A patent/BR0115306B1/pt not_active IP Right Cessation
- 2001-11-16 PT PT01982800T patent/PT1334106E/pt unknown
- 2001-11-16 AT AT05077705T patent/ATE533768T1/de active
- 2001-11-16 ES ES01982800T patent/ES2260303T3/es not_active Expired - Lifetime
- 2001-11-16 SI SI200130590T patent/SI1334106T1/sl unknown
- 2001-11-16 PE PE2001001147A patent/PE20020596A1/es active IP Right Grant
-
2003
- 2003-04-28 IL IL155624A patent/IL155624A/en not_active IP Right Cessation
- 2003-05-16 NO NO20032234A patent/NO326366B1/no not_active IP Right Cessation
-
2005
- 2005-08-31 JP JP2005252651A patent/JP4427496B2/ja not_active Expired - Fee Related
- 2005-10-18 AU AU2005225035A patent/AU2005225035B2/en not_active Ceased
-
2006
- 2006-06-26 CY CY20061100867T patent/CY1105423T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR034854A1 (es) | Compuesto de imidazol condensado, prodroga del mismo, composición farmaceutica y agente para reducir androgenos que lo contienen ,metodo para producirlo, sal diastereomerica de dicho compuesto y metodo para producir un compuesto opticamente activo del compuesto | |
| AR053162A1 (es) | Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma. | |
| PE20181045A1 (es) | Compuestos utiles como inmunomoduladores | |
| SV2008002969A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| PE20020348A1 (es) | Exemestano como agente quimiopreventivo | |
| UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
| CL2008003431A1 (es) | Compuestos derivados de nucleosidos 2',4' sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih. | |
| UY27503A1 (es) | Nuevos derivados de piperazina | |
| CL2011000653A1 (es) | Compuestos derivados del acido 1-amino-2-ciclobutil-etil-boronico; composicion farmaceutica; polvo liofilizado y metodo para obtenerlo; y uso en el tratamiento del cancer. | |
| CL2009000780A1 (es) | Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k. | |
| CL2004000848A1 (es) | Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras | |
| MX2024009926A (es) | Composiciones y metodos para tratar trastornos del snc. | |
| AR070026A1 (es) | Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus | |
| MX2025007218A (es) | Moduladores del inflamasoma nlrp3 y productos y metodos relacionados | |
| AR034120A1 (es) | Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico | |
| AR039190A1 (es) | Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto | |
| PA8542901A1 (es) | Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple | |
| BR0208017A (pt) | Combinação compreendendo combretastatina e agentes anticâncer | |
| AR130828A1 (es) | Método para tratar el cáncer | |
| MX2019004842A (es) | Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc. | |
| AR044869A1 (es) | Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, su uso para fabricar un medicamento y procedimiento para su preparacion | |
| AR028987A1 (es) | Compuesto derivado de ciclopentapiridin-cetona, composicion farmaceutica que lo contiene y su uso en la fabricacion de un medicamento util para tratar una enfermedad | |
| CU20190095A7 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| CR9539A (es) | 4-anilino-3-quinolinocarbonitrilos para el tratamiento de cancer | |
| AR083780A1 (es) | Composicion farmaceutica para tratar infecciones del hcv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |